Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

Finerenone further reduces albuminuria in patients already on triple therapy for CKD with type 2 diabetes (SGLT2i, GLP-1 RA, ...

Investigational product demonstrated superior hemodialysis vascular access outcomes compared with autologous arteriovenous ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...

Dr Ubel’s call for ethical guidance comes amid rapid growth in private equity acquisition of physician practices. According to a 2023 report titled “Monetizing Medicine: Private Equity and Competition ...

Use vs non-use of sodium-glucose cotransporter 2 inhibitors by older patients with CKD stages 4-5D is significantly associated with reductions in all-cause mortality risk at 6, 12, and 60 months.

Elevated CRP levels in patients with ASCVD should prompt clinicians to screen and monitor patients for kidney injury. Elevated C-reactive protein levels in patients with atherosclerotic cardiovascular ...

Unless an app is provided by a covered entity or its business associate, HIPAA rules do not protect the privacy of data ...

Racial disparities have persisted over the past 2 decades in access to preemptive living donor kidney transplantation, ...

Empagliflozin continues to provide cardiorenal benefit in patients with chronic kidney disease (CKD) for up to 12 months ...

West African individuals with just 1 allele variant in the APOL1 gene are at increased risk for chronic kidney disease (CKD), especially focal segmental ...